FORM PTO-1390 (Modified)
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE
(REV 12-2004)

	TF	RANSMITTAL LETTER TO THE UNITED STATES	ATTORNEY'S DOCKET NUMBER
		DESIGNATED/ELECTED OFFICE (DO/EO/US)	059893-0121
	(CONCERNING A FILING UNDER 35 U.S.C. 371	U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/586,310
1		IONAL APPLICATION NO. INTERNATIONAL FILING DATE 1/14/2005	PRIORITY DATE CLAIMED 1/16/2004
		INVENTION 1 (NDC2) AND METHODS OF IDENTIFYING LICANDS THEREOF	
		1 (NPC3) AND METHODS OF IDENTIFYING LIGANDS THEREOF IT(S) FOR DO/EO/US	
	Margari	ita GARCIA-CALVO erewith submits to the United States Designated/Elected Office (DO/EO/	(US) the following items and other information:
	_		
1.		This is a FIRST submission of items concerning a filing under 35 U.S.	
2.	\boxtimes	This is a SECOND or SUBSEQUENT submission of items concerning	
3.		This is an express request to begin national examination procedures items (5), (6), (9) and (21) indicated below.	(35 U.S.C. 371(f)). The submission must include
4.		The US has been elected (Article 31).	
5.		A copy of the International Application as filed (35 U.S.C. 371(c)(2))	
		is attached hereto (required only if not communicated by the Ir	nternational Bureau).
		has been communicated by the International Bureau.	
		is not required, as the application was filed in the United States	s Receiving Office (RO/US)
6.		An English language translation of the International Application as file	ed (35 U.S.C. 371(c)(2)).
		is attached hereto.has been previously submitted under 35 U.S.C. 154(d)(4).	· · · · · · · · · · · · · · · · · · ·
7.		Amendments to the claims of the International Application under PCT	Article 19 (35 U.S.C. 371(c)(3))
	<u> </u>	are attached hereto (required only if not transmitted by the Inte	
		have been communicated by the International Bureau.	to the last has NOT assisted
		have not been made; however, the time limit for making such ahave not been made and will not be made.	amendments has NOT expired.
8.		An English language translation of the amendments to the claims und	der PCT Article 19 (35 U.S.C. 371(c)(3)).
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).	
10.		An English language translation of the annexes to the International P	reliminary Examination Report under PCT Article
		36 (35 U.S.C. 371(c)(5)).	
ltem	s 11 to	20 below concern other document(s) or information included:	
11.	\boxtimes	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.	
12.		An assignment document for recording. A separate cover sheet in co	ompliance with 37 CFR 3.28 and 3.31 is included.
13.		A preliminary amendment.	•
14.		An Application Data Sheet under 37 CFR 1.76.	
15.		A substitute specification.	
16.		A power of attorney and/or change of address letter.	
17.		A computer-readable form of the sequence listing in accordance with	PCT Rule 13 <i>ter</i> .2 and 37 CFR 1.821 – 1.825
18.		A second copy of the published international application under 35 U.S.	
19.		A second copy of the English language translation of the international	
20.		Other items or information:	
	_	1390 (Modified)	

u.s. APPLICA 10/586	-	own, see 37 CFF	, i	NTERNATIONAL APPLICATION N PCT/US2005/001469	VO .		rs docki 3-0121	ET NUMBER	
	The followi	ng fees have	been sul	omitted:					
21.	Basic nati	•				80	\$	0.00	
	ons of PCT			ort prepared by USPTO an	d all clai	ns satisfy	\$	0.00	
23.	Search fe	ee							
			has been	paid on the international	applicati	on to the			
		national Sea							
			-	provided to the Office					
		Report prepa	red and p	hovided to the Office			•	0.00	
All other s		TAL OF AR	DVE 24	22 and 23 =			\$	0.00	**************************************
					OO shoo	te (eveluding	Ψ	0.00	
sequ	ence listing	or computer	program	wings filed in paper over 1 listing filed in an electronic aper or fraction thereof.	c mediun	n). The fee			
Total She	ets Extra	sheets		r of each additional 50 or found up to a whole num		RATE			
- =	:	=				×	\$	0.00	
Surcharge	e of \$130.00) for furnishi	ng the oa	th or declaration later that	n 30 moi	nths from the	\$	0.00	
		ty date (37 C							
CL	AIMS	NUMBER	FILED	NUMBER EXTRA		RATE	\$		
Total	Claims	20	- 20 =	0	x \$	50.00	\$	0.00	
Independ	ent Claims	2	- 3 =	0	x \$	200.00	\$	0.00	
· · · · · · · · · · · · · · · · · · ·	•	ENT CLAIM(licable)	+ \$	360.00	\$		
WOLTH L			<u> </u>	TOTAL OF ABOV			\$	0.00	
	lit-loi	nee one all one	it cototus	A			\$	0.00	
	educed by 1/2		ity status	. See 37 CFR 1.27. Fees	above at		•		
					S	UBTOTAL =	\$	0.00	
	_			English translation later the FR 1.492(i)).	an 30 mo	onths	\$		
				TOTA	AL NATI	ONAL FEE =	\$	0.00	
				t (37 CFR 1.21(h)). The aset (37 CFR 3.28, 3.31). 40			\$		
		h h v a h v v ava a				NCLOSED =	\$	0.00	
	<u> </u>	_					A	mount to be	
								refunded:	
								charged:	
a. 🗌	A check i	n the amou	nt of \$	0.00 to cover the above	e fees is	enclosed.	-		
b. 🗌				Account No. <u>19-0741</u> in a	the amo	ount of \$ 0.0	00 to co	over the above	fees.
c. 🛛	The Com	missioner in	s hereb	y authorized to charge count No. <u>19-0741</u> . A de	any ad uplicate	ditional fees copy of this	which sheet i	may be requir s enclosed.	ed, or credit any
d. 🗌	Fees are informati	to be charg on should	e to a c not be	redit card. WARNING: included on this form.	Informa Provide	tion on this fo	orm ma informa	ny become pub ation and autho	lic. Credit card orization on PTO-
	2038.								
NOTE: 1.137(a)	Where ar or (b)) mu	appropria est be filed	ate time and gr	e limit under 37 CFR ranted to restore the In	1.495 h iternatio	as not been onal Applica	n met, ation to	a petition to pending stat	revive (37 CFR
SEND A		ESPONDEI	NCE TO).		1		H	
OLIND A	LL OUNK		10L 10	••		SIGNATI	IRF		
	Folev &	Lardner Ll	P			Rouget		schol	
	•	er Number		3			. 116113	301161	
	Justonic	, Hullinel	. <u>~</u> ~ ~ ~ (•		NAME			
					•	39,221	D 4 T 1 D		····
						REGIST	RATIO	N NUMBER	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Margarita GARCIA-CALVO

Title:

NPC1L1 (NPC3) AND

METHODS OF IDENTIFYING

LIGANDS THEREOF

Appl. No.:

10/586,310

International

1/14/2005

Filing Date:

371(c) Date:

Unassigned

Examiner:

Unassigned

Art Unit:

Unassigned

Confirmation

Unassigned

Number:

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56.

STATEMENT

Pursuant to the duty of disclosure under 37 CFR § 1.56, it is requested that the documents listed on the accompanying Form PTO/SB/08 be considered and made of record in the above-identified patent application. Other than cited U.S. patents and published applications, copies of these documents are enclosed. Since the Examiner is believed to have ready access to the cited U.S. patents and published patent applications, copies of these documents are not herewith transmitted, but will be provided upon request.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing of a first office action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicant respectfully requests that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEES

No office action on the merits of the application has yet been received; accordingly, Applicants believe that no fee is required. If however, any fees are due, the Office may charge such fees to Deposit Account No. 19-0741.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment form being unsigned, providing incorrect information resulting in a rejected credit card transaction, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Rouget F. Henschel

Attorney for Applicant

Registration No. 39,221

25-0ct-2006

FOLEY & LARDNER LLP

Customer Number: 22428 Telephone:

(202) 295-4059

Facsimile:

(202) 672-5399

RFHE:kdm

Attachment: PTO/SB/08 and 46 references

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute fo	or form 1449B	J/PTO	Complete if Known			
	INFORMATI	ON DISCLO	SURE	Application Number	10/586,310		
	STATEMEN	T BY APPL	ICANT	Filing Date	1/14/2005		
	Data Submitta	d: Ostobor 1	25 2006	First Named Inventor	Margarita GARCIA-CALVO		
	Date Submitte	d. October 2	25, 2006	Group Art Unit	Unassigned		
	(use as many s	sheets as ne	ecessary)	Examiner Name	Unassigned		
Sheet	1	of 5	Attorney Docket Number	059893-0121			

		II C Detent De	a compani			Pages, Columns, Lines,
Examiner Initials*	Cite No. ¹	U.S. Patent Do	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
		2004/0093629		Altmann et al.	05/13/2004	
	<u>. </u>	2004/0137467		Altmann et al.	07/15/2004	
		2004/0161838		Altmann et al.	08/19/2004	
		6,426,198		Cartsea et al.	06/30/2002	
		2002/0151536		Davis et al	10/17/2002	
		RE37,721		Rosenblum et al.	05/28/02	
		5,306,817		Thiruvengadam et al.	04/26/1994	· ·
		5,561,227		Thiruvengadam et al.	10/01/1996	
		5,618,707		Homann et al.	04/08/1997	
		5,624,920		McKittrick et al.	04/29/1997	
· ·		5,631,365	· · · · · · · · · · · · · · · · · · ·	Rosenblum et al.	05/20/1997	
		5,656,624		Vaccaro et al.	08/12/1997	
		5,627,176		Kirkup et al.	05/06/1997	
····		5,633,246		McKittrick et al.	05/27/1997	
,		5,661,145		Davis	08/26/1997	
		5,688,785		Vaccaro	11/18/1997	
		5,688,787		Burnett et al.	11/18/1997	
		5,688,990		Shankar	11/18/1997	
		5,698,548		Dugar et al.	12/16/1997	
		5,728,827		Thiruvengadam et al.	03/17/1998	
 		5,739,321		Wu et al.	04/14/1998	
		5,744,467		McKittrick et al.	04/28/1998	
		5,756,470		Yumibe et al.	05/26/1998	
· · · · · · · · · · · · · · · · · · ·		5,767,115		Rosenblum et al.	06/16/1998	
		5,846,966		Rosenblum et al.	12/08/1998	
		5,856,473		Shankar	01/05/1999	
		5,886,171		Wu et al.	03/23/1999	
		5,919,672		Homann <i>et al</i> .	07/06/1999	
<u> </u>		6,093,812		Thiruvengadam et al.	07/25/2000	

eş en		
 Date		Examiner
Considered		Signature
 Considered		Signature

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute f	or form 1449B	/PTO	Complete if Known			
	INFORMAT	ION DISCLO	SURE	Application Number	10/586,310		
	STATEMEN	IT BY APPLI	ICANT	Filing Date	1/14/2005		
	Data Submitte	ad: Oatabar 1	25 2006	First Named Inventor	Margarita GARCIA-CALVO		
	Date Submitte	ed. October 2	25, 2006	Group Art Unit	Unassigned	<u> </u>	
	(use as many	sheets as ne	cessary)	Examiner Name	Unassigned		
Sheet	2	of	5	Attorney Docket Number	059893-0121		

		U.S. PATENT DOCUME	NTS	
	U.S. Patent Docume	ent		
······································	6,096,883	Wu et al.	08/01/2000	
	6/133,001	Homann et al.	10/17/2000	
	6,207,822	Thiruvengadam et al.	03/27/2001	
	6,627,757	Fu <i>et al</i> .	09/30/2003	
<u>. </u>	6,632,933	Altmann et al.	10/14/2003	
	6,593,078	Altmann et al.	07/15/2003	

			ONFODEISI	HED U.S. PATENT APPLICATION	DOCUMENTS		
Examiner	Cite	U.S. Patent Application Document		Name of Patenton or Applicant of	Filing Date of	Pages, Columns, Lines, Where Relevant	
Initials*	No. ¹	Serial Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	

				FOR	EIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No. ¹	Fo Office ³	reign Patent Document Number ⁴ Kind Co	ode ⁵	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
			WIPO	WO2006015365	A1	Mt. Sinai School of Med.	02/09/2006	rigures Appear
		VVII	W0200013303		With Siliar School of Wed.	02/03/2000		
		WIPO	WO2005/69900		Merck & Co.	08/04/2005		
		WIPO	WO2004/032716	A2	Massachusetts Institute	04/22/2004		
	ļ				of Technology			
		WIPO	WO 01/70974		Takeda Chemical Industries, Ltd.	09/27/2001		
		WIPO	WO 01/57190		HYSEQ, Inc	08/09/2001		
		WIPO	WO 03/100094		DEVGEN NV	12/04/2003		
4,		WIPO	WO 00/20623		Schering Corporation	04/13/2000		
		WIPO	WO 00/34240		Schering Corporation	06/15/2000		
n		WIPO	WO 00/60107		Schering Corporation	10/12/2000		
		WIPO	WO2004/014947	A1	Aventis Pharma Deutschland GmBH	02/19/2004		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute f	or form 1449B	/PTO	Complete if Known				
	INFORMAT	ION DISCLO	SURE	Application Number	10/586,310	 -		
	STATEMEN	IT BY APPLI	CANT	Filing Date	1/14/2005	, , , , , , , , , , , , , , , , , , ,		
	Data Submitte	ad: Ostobor T)5 200e	First Named Inventor	Margarita GARCIA-CALVO			
	Date Submitte	ed. October 2	25, 2006	Group Art Unit	Unassigned			
	(use as many	sheets as ne	cessary)	Examiner Name	Unassigned			
Sheet	3	of	5	Attorney Docket Number	059893-0121			

					FOR	EIGN PATENT DOCUME	NTS		
Examiner Initials*	Cite No.1	Fo Office ³	reign Patent D Number ⁴	Document Kind Cod (if known		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		WIPO	WO 00/637	703		Schering Corporation	10/26/2000		
		WIPO	WO 02/079	9174		Schering Corporation	10/10/2002		
. ***		WIPO	WO 01/750	067	A2	HYSEQ, Inc.	10/11/2001		
		WIPO	WO 01/750 Search Re		A3	HYSEQ, Inc.	10/11/2001		

·		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
		ERICKSON et al., J. Neuroscience Research, June 2002, pp. 738-744, Vol. 68.	
		ERICKSON <i>et al.</i> , J. Inher. Metab. Dis., Feb. 2000, pp. 54-62, Vol. 23.	-
		ERICKSON et al., Molecular Reproduction and Development, 2002, pp. 167-173, Vol. 62,.	
	, ,,, 	ALTMANN et al., Science., Feb 2004, pp. 1201-1204, Vol. 303.	
		DAVIES et al., The Journal of Biological Chemistry, April 1, 2005, pp. 12710-12720, Vol. 280, No. 13.	
		IOANNOU, Nat. Rev. Molecular Cell Biology, Sep. 2001, pp. 657-668, Vol. 2.	
		BLOM et al., Human Molecular Genetics, 2003, pp. 257-272, Vol. 12, No. 3.	
		MINHAS, Br. J. Cardiol., 2003, pp. 59-68, Vol. 10.	
		Abstracts 1-79, The International Conference on Niemann-Pick Type C Disease, May 29-31, 2003; Tuscon, Arizona.	
		CARSTEA et al., Science, 1997, Vol. 277, pp. 0228-231.	

Examiner	Date	
Signature	/Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute fo	or form 1449B/I	PTO	Complete if Known		
	INFORMATI	ON DISCLOS	SURE	Application Number	10/586,310	
	STATEMEN	T BY APPLIC	CANT	Filing Date	1/14/2005	
Date Submitted: October 25, 2006				First Named Inventor	Margarita GARCIA-CALVO	
	Date Submitte	d. October 2:	5, 2006	Group Art Unit	Unassigned	
	(use as many s	sheets as ned	cessary)	Examiner Name	Unassigned	
Sheet	4	of	5	Attorney Docket Number	059893-0121	

NON PATENT LITERATURE DOCUMENTS									
Examiner Initials*	Cite No. ¹	A III IIAM INAAK MAAATINA IAIITAA GARIAI GUMNAGIIIM CATAIAA AIC IAATA NAAAIGI VAIIIMA-IGGIIA NIIMAATIGI							
		Genbank Sequence Disclosure; Accession No. AF192522.							
	· · · · · · · · · · · · · · · · · · ·	Genbank Sequence Disclosure; Accession No. AF002020.							
		Genbank Sequence Disclosure, Accession No. AK078947.							
· · · · · · · · · · · · · · · · · · ·		DAVIES <i>et al.</i> , Genomics, 2000, pp. 137-145, Vol. 65, Issue 2.							
		IOANNOU <i>et al.</i> , Mol. Genet. Metab., 2000, pp. 175-181, Vol. 71, No. 1-2.							
		ALTMANN et al., Biochim. Biophys. ACTA, 2002, pp. 77-93, Vol. 1580.							
	·	DENINNO et al., J. Med. Chem., 1997, Vol. 40, pp. 2547-2554, No. 16.							
		KRAMER <i>et al.</i> , Falk Symposium 129, 2002, pp. 147-160, Vol. 129.							
		AMIGO <i>et al.</i> , Hepatology, 2002, Vol. 36, pp. 819-828, No. 4.	·						
		REPA <i>et al.</i> Journal of Lipid Research, 2002, pp. 1864-1874, Vol. 43.							
		HAUSER et al., Biochemistry, 1998, Vol. 37, pp. 17843-17850, No. 51.							
		ACTON et al., The Journal of Biological Chemistry, 1994, Vol. 269, pp. 21003-21009, No. 33.							
		HERNANDEZ et al., Biochimica et Biophysica Acta, 2000, pp. 232-242, Vol. 1486.							
·		DETMERS <i>et al.</i> , Biochimica et Biophysica Acta, 2000, pp. 243-252, Vol. 1486.							
		SMART <i>et al.</i> , Proc. Natl. Acad. Sci., 2004, pp. 3450-3455, Vol. 101, No. 10.							

	The same against the same and the same against the same a		
Examiner		Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for	form 1449B/	/PTO	Complete if Known		
	INFORMATIO	N DISCLO	SURE	Application Number	10/586,310	
	STATEMENT	BY APPLI	CANT	Filing Date	1/14/2005	
	Data Submitted	· October 2	5 2006	First Named Inventor	Margarita GARCIA-CALVO	
	Date Submitted	. October 2	.5, 2006	Group Art Unit	Unassigned	
	(use as many sh	ieets as ne	cessary)	Examiner Name	Unassigned	
Sheet	5	of	5	Attorney Docket Number	059893-0121	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		DAWSON <i>et al.</i> , Curr. Opin. Lipidol, 1999, pp. 315-320, Vol. 10, No. 14.	
		ALLAYEE et al., Science, 2000, pp. 1709-1711, Vol. 290, No. 5497.	
		BERGE <i>et al.</i> , Science, 2000, pp. 1771-1775, Vol. 290, No. 5497.	
		JOURDHEUIL-RAHMANI et al., Biochem Biophys Res. Commun., 2002, pp. 390-395, Vol. 292, No2.	,
		WERDER <i>et al.</i> , Biochemistry, 2001, pp. 11643-11650, Vol. 40, No. 38.	
,, <u>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</u>		Zetia™ Product Information Sheet.	
		Mouse Gene Informatics web page "Gene Detail" of the NPC1L1 gene.	

	1	
Examiner	Date	
Signature	Considered	
	· · · · · · · · · · · · · · · · · · ·	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.